ArticleHeliyon2023
Multidrug-resistant
Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Genomic and phenotypic characterization of non-O157 Shiga toxin-producingMicrobiology spectrum · 2026Article
- Molecular determinants of antimicrobial resistance inMicrobiology spectrum · 2026Article
- Fecal sludge and adjacent drinking water as reservoirs of multidrug resistant ESBL-producing pathogenic Escherichia coli in Rohingya Camps, Bangladesh.Scientific reports · 2026Article
- Virulence Traits and Drug Resistance of STEC Isolated from Layer Poultry andMicroorganisms · 2026Article
- Genomic characterization of multidrug-resistant Escherichia coli strains identified from patients with urinary tract infection in Egypt.Scientific reports · 2026Article
- Article
- Article
- Unravelling the Antibiotic Resistance: Molecular Insights and Combating Therapies.Applied biochemistry and biotechnology · 2025Review
- Multidrug-resistant ESBLHeliyon · 2025Article
- Article
- Genome sequencing of3 Biotech · 2025Article
- Genotypic Characterisation and Antimicrobial Resistance of Extended-Spectrum β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2024Article
- Isolation and characterization of cefotaxime resistantHeliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 3 countries.
Funding
Abstract
Extended spectrum β-lactamase producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.